ANO1 and neoplasm: Together, these data support an integrated approach in which tumor size and Ki-67—interpreted alongside CD117, DOG1, and CD34, and complemented by molecular testing (KIT, PDGFRA, MMR status)—may contribute to diagnostic assessment and hypothesis generation for future risk stratification [2,16,31,32,33].